Access to toxicity study reports and protection of commercial interests

Written By

kevin munungu Module
Kevin Munungu Lungungu

Senior Associate
Belgium

I am a senior associate in the Regulatory, Public & Administrative Law department in our Brussels office. I advise both Belgian and international clients on regulatory matters across several sectors, especially in the Life Sciences and the Energy sectors.

Gerard Hogan, Advocate General at the Court of Justice of the European Union (“CJEU”) recently delivered an opinion in the pending case between MSD Animal Health Innovation (“MSD”), Intervet international (“Intervet”) and the European Medicines Agency (“EMA”). In his opinion, due to their commercial value toxicity study reports are covered by a general presumption of confidentiality and their disclosure may only be granted under very strict conditions. 

Accordingly, Advocate General Hogan recommends the annulment of the General Court’s previous judgment, which ruled in favour of the widest possible access to such reports. Although the Advocate General’s opinions are not binding this position illustrates the ongoing contest before the CJEU on one of the major topics for the life-science industry. 

View the full article in our BioTalk blog.

 

Latest insights

More Insights
featured image

Employment Litigation in Singapore: Employees Can Double-Strike with Employment Claims Tribunal Win Followed by High Court Claim

4 minutes Jul 11 2025

Read More
Curiosity line green background

Sprinting to an IPO? ASIC trials a streamlined fast-track to the ASX

Jul 08 2025

Read More
featured image

EPO Upholds, UPC Revokes: A Tale of Diverging Views on PCSK9 Antibody Patent

2 minutes Jul 02 2025

Read More